Status: Recruiting
Development of a Database to Investigate Digital and Blood-Based Biomarkers and Their Relationship to Tau and Amyloid PET Imaging in Older Participants Who Are Cognitively Normal (CN), Have Mild Cognitive Impairment (MCI), or Have Mild-to-Moderate AD Dementia
Bio-Hermes-002 is a 120-day cross-sectional study that will result in a blood, CSF, retinal, digital, MRI, and PET brain imaging biomarker database that can be used to determine the primary objective. Digital biomarkers and blood-based biomarkers will be tested to determine whether a meaningful relationship exists between biomarkers alone or in combination with tau or amyloid brain pathology identified through PET images.
Participants needed: 1,200
Trial details
Age: 60-90Biological sex: AllType: ObservationalSponsor: GAP Innovations, PBCUpdated: Apr 15, 2026Locations: 26
Eligibility criteria
Participant is between 60 to 90 years of age (inclusive) at the time of consent;... [+7]
Participant is unable to undergo amyloid and tau PET scans due to self-reported... [+26]